Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

Abstract

PURPOSE Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improve clinical outcomes in patients with B-cell lymphomas who were previously rituximab resistant, defined as no… (More)
DOI: 10.1158/1078-0432.CCR-14-2221

Topics

1 Figure or Table

Cite this paper

@article{Chong2015CombinationOL, title={Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.}, author={Elise A. Chong and Tahamtan Ahmadi and Nicole A. Aqui and Jakub Svoboda and Sunita Dwivedy Nasta and Anthony R Mato and Kristy M. Walsh and S. Schuster}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2015}, volume={21 8}, pages={1835-42} }